Oxford Biomedica plc
OXB.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | £336 | £445 | £312 | £212 |
| - Cash | £54 | £61 | £81 | £104 |
| + Debt | £105 | £109 | £110 | £111 |
| Enterprise Value | £387 | £493 | £341 | £220 |
| Revenue | £73 | £78 | £51 | £46 |
| % Growth | -6.1% | 53.5% | 9.3% | – |
| Gross Profit | £32 | £35 | £18 | £18 |
| % Margin | 43.2% | 44.5% | 35.3% | 38.3% |
| EBITDA | -£6 | £5 | -£20 | -£112 |
| % Margin | -8.3% | 6.4% | -38.7% | -241.5% |
| Net Income | -£26 | -£11 | -£32 | -£110 |
| % Margin | -36% | -13.7% | -63.9% | -235.7% |
| EPS Diluted | -0.25 | -0.1 | -0.31 | -1.13 |
| % Growth | -150% | 67.7% | 72.6% | – |
| Operating Cash Flow | £2 | -£12 | -£39 | -£23 |
| Capital Expenditures | -£2 | -£3 | -£5 | -£5 |
| Free Cash Flow | £1 | -£15 | -£44 | -£28 |